Jensen TE, Rose AJ, Jørgensen SB, Brandt N, Schjerling P, Wojtaszewski JF, Richter EA. Possible CaMKK-dependent regulation of AMPK phosphorylation and glucose uptake at the onset of mild tetanic skeletal muscle contraction. Am J Physiol Endocrinol Metab 292: E1308 -E1317, 2007. First published January 9, 2007; doi:10.1152/ajpendo.00456.2006 /calmodulin (CaM) competitive inhibitor KN-93 has previously been used to evaluate 5Ј-AMP-activated protein kinase (AMPK)-independent Ca 2ϩ -signaling to contraction-stimulated glucose uptake in muscle during intense electrical stimulation ex vivo. With the use of low-intensity tetanic contraction of mouse soleus and extensor digitorum longus (EDL) muscles ex vivo, this study demonstrates that KN-93 can potently inhibit AMPK phosphorylation and activity after 2 min but not 10 min of contraction while strongly inhibiting contraction-stimulated 2-deoxyglucose uptake at both the 2-and 10-min time points. These data suggest inhibition of Ca 2ϩ /CaM-dependent signaling events upstream of AMPK, the most likely candidate being the novel AMPK kinase CaM-dependent protein kinase kinase (CaMKK). CaMKK protein expression was detected in mouse skeletal muscle. Similar to KN-93, the CaMKK inhibitor STO-609 strongly reduced AMPK phosphorylation and activity at 2 min and less potently at 10 min. Pretreatment with STO-609 inhibited contraction-stimulated glucose uptake at 2 min in soleus, but not EDL, and in both muscles after 10 min. Neither KN-93 nor STO-609 inhibited 5-aminoimidazole-4-carboxamide-1-␤-4-ribofuranoside-stimulated glucose uptake, AMPK phosphorylation, or recombinant LKB1 activity, suggestive of an LKB1-independent effect. Finally, neither KN-93 nor STO-609 had effects on the reductions in glucose uptake seen in mice overexpressing a kinase-dead AMPK construct, indicating that the effects of KN-93 and STO-609 on glucose uptake require inhibition of AMPK activity. We propose that CaMKKs act in mouse skeletal muscle regulating AMPK phosphorylation and glucose uptake at the onset of mild tetanic contraction and that an intensity-and/or time-dependent switch occurs in the relative importance of AMPKKs during contraction.
bolic stress and is activated during contraction, its involvement in contraction-stimulated glucose uptake is an obvious hypothesis and has been studied extensively (17, 25) . Although studies using various transgenic mouse models have demonstrated that glucose uptake stimulation by the adenosine analog 5-aminoimidazole-4-carboxamide-1-␤-4-ribofuranoside (AICAR) requires expression of the catalytic ␣ 2 -AMPK, the regulatory ␥ 3 -subunit of AMPK, and the AMPK kinase (AMPKK) LKB1 (4, 26, 31, 37) , the necessity of AMPK activity during contraction is more controversial. Hence, some transgenic mouse models present considerable effects of reduced total AMPK activity on contraction-stimulated glucose uptake (31, 37) while others do not (16, 26) .
Increasing cytosolic Ca 2ϩ concentration below the contraction threshold significantly enhances glucose uptake in isolated rat soleus and epitroclearis muscle without an apparent increase in AMPK phosphorylation (7, 56, 57, 59) , suggesting that Ca 2ϩ may also provide a signal to increase glucose uptake during contraction. Two studies utilizing the calmodulin (CaM)-competitive inhibitor of CaM-dependent protein kinase (CaMK) I, CaMKII, and CaMKIV (KN-62) or its more potent structural analog KN-93 (10, 19, 43, 49) have implicated the CaMKs in this respect (56, 57) . Although KN compounds have been reported to inhibit AMPK activation in response to an intracellular Ca 2ϩ -increasing stimulus in pancreatic MIN-6 cells (29) , KN-93 does not seem to affect AMPK phosphorylation in rat muscle during intense ex vivo contraction (57) . It has been proposed (56, 57) , based on the potency of the KN compounds and additivity studies using AICAR and caffeine, that AMPK and Ca 2ϩ signaling each account for ϳ50% of the maximal contraction-stimulated glucose uptake response in the fast-twitch rat epitroclearis muscle, whereas CaMKs, but not AMPK, are the predominant mediators of contraction-stimulated glucose uptake in the slow-twitch rat soleus muscle.
Several recent studies have shown that Ca 2ϩ signaling may activate AMPK by CaMK kinase (CaMKKs)-dependent phosphorylation (18, 21, 22, 54) , and a growing number of studies indicate that AMPK activity may be coregulated by LKB1 and CaMKKs in various cell types (3, 5, 11, 29, 38, 42, 45) . However, although CaMKK protein expression has been reported in human skeletal muscle (34) , the striking lack of ␣ 2 -AMPK activation and potent inhibition of glucose uptake during intense electrical stimulation of mouse muscles lacking LKB1 expression have so far suggested that LKB1 is the principal donor of AMPKK activity in mouse skeletal muscle during contraction (37, 48) .
In this study, the effects of KN-93 and STO-609 on AMPK activation and glucose uptake during low-intensity tetanic ex vivo contraction were evaluated. Our data suggest that CaMKKs act in mouse skeletal muscle regulation of AMPK phosphorylation and glucose uptake at the onset of mild tetanic contraction and that an intensity-and/or time-dependent switch may occur in the relative importance of AMPKKs during contraction.
METHODS
Muscle-specific kinase-dead ␣2-AMPK mice. C57BL/6 mice overexpressing a kinase-dead Lys 45 Arg mutant ␣2-protein, driven by the heart-and skeletal muscle-specific creatine kinase promoter, have been described previously (31) and were a kind gift from Morris J. Birnbaum, Pennsylvania School of Medicine. Female hemizygous transgenic mice and wild-type mice (8 -20 wk of age) used were littermates from intercross breeding of hemizygous transgenic mice and wild-type mice. The animals were maintained on a 10:14-h light-dark cycle and received standard rodent diet (Altromin no. 1324; Chr. Pedersen, Ringsted, Denmark) and water ad libitum. All experiments were approved by the Danish Animal Experimental Inspectorate and complied with the "European Convention for the Protection of Vertebrate Animals Used for Experiments and Other Scientific Purposes."
Muscle incubation. Soleus and extensor digitorum longus (EDL) muscles were obtained from fed anesthetized mice (6 mg pentobarbital sodium/100 g body wt) and suspended at resting tension (4 -5 mN) in incubation chambers (Multi Myograph system; Danish MyoTechnology, Aarhus, Denmark) in Krebs-Ringer-Henseleit (KRH) buffer supplemented with 0.1% BSA, 2 mM pyruvate, and 8 mM mannitol at 30°C, as described previously (26) . The muscles were incubated for 1 h with 10 M KN-93 (Calbiochem, Nottingham, UK), 5 M STO-609 (Calbiochem), or a corresponding amount of DMSO as a vehicle control. The incubation chambers were kept dark to avoid degradation of light-sensitive compounds. Following the first hour, contractions were induced by electrical stimulation every 15 s with 1-s trains of 0.2-ms impulses delivered at 100 Hz (ϳ30 V) for up to 10 min. For AICAR stimulation, the muscles were further incubated for 40 min in KRH buffer containing 2 mM AICAR with or without the inhibitors. To evaluate the effect of hook up at resting tension in our incubation apparatus on muscle signaling, muscles were harvested immediately postexcission or after 1 h incubation with or without being suspended at resting tension. Force development was measured during incubations by a force transducer hooked to one end of the muscles. Total (integrated) force production during 10 min of electrical stimulation was used to evaluate fatigue development.
2-Deoxyglucose uptake. 2-Deoxyglucose (2-DG) uptake was measured for 10 min immediately after cessation of either 0, 2, or 10 min of electrical stimulation or 40 min of AICAR treatment using radioactive tracers as described previously (26) .
Muscle analyses. At 0, 2, and 10 min of contraction or 40 min of AICAR treatment, muscles were frozen with aluminum tongs precooled in liquid nitrogen and stored at Ϫ80°C. Muscles were homogenized (PT 3100; Brinkmann Instruments) in ice-cold buffer (50 mM Tris ⅐ HCl, 10% glycerol, 1 mM EDTA, 5 mM EGTA, 50 mM NaF, 5 mM Na 4P2O7, 2 mM Na3VO4, 1 mM phenylmethylsulfonyl fluoride, 1 mM dithithreitol, 1 mM benzamidine, 1% Nonidet P-40, and protease inhibitor cocktail, pH 7.4) and rotated end over end for 1 h at 4°C. Lysates were generated by centrifugation (17,500 g) for 1 h at 4°C.
Immunoblotting. Total protein and phosphorylation levels of relevant proteins were determined by standard immunoblotting techniques, as described previously (26 skim milk protein for 1-2 h at room temperature. Membranes were incubated with primary antibodies overnight at 4°C, followed by incubation with horseradish peroxidase-conjugated secondary antibody for 2 h at room temperature (DAKO). Bands were visualized using an Eastman Kodak Image Station 2000MM and enhanced chemoluminescence (ECL ϩ ; Amersham Biosciences). ␣1-and ␣2-AMPK activity. Isoform-specific ␣-AMPK activity was measured in vitro in sequential immunoprecipitations (IPs) from 100 g of muscle lysate protein using anti-␣ 1-and anti-␣2-antibodies. The protocol was identical to the one described previously (26) , except that 200 M AMARA peptide (Schafer-N) was used instead of SAMS peptide.
LKB1 and CaMKK activities. The activity of 30 ng of recombinant LKB1/MO25/STRAD complex (no. 14 -596; Upstate Biotechnologies, Lake Placid, NY) against 10 g of LKBtide (no. 12-540; Upstate Biotechnologies) was assessed using the buffers and procedures provided by the manufacturer, running the assay for 10 min at 30°C. Recombinant CaMKK␤ (50 ng/ml) was run against 10 g of glutathione S-transferase-CaMKI (both a kind gift from A. M. Edelman, State University of New York) in assay buffer (50 mM HEPES, 5 mM MgCl 2, 1 mM EGTA, 1 mM Na4P2O7, pH 7.4) with or without 2 mM CaCl2 and 0.5 M CaM (no. 14 -368; Upstate Biotechnologies) and was assayed for 30 min at 30°C. CaMKK␣ and -␤ activities were measured on IPs of mouse brain lysate (20 g) using two polyclonal CaM affinity precipitation. To assess Ca 2ϩ -dependent CaM binding of selected proteins, 500 g of mouse quadriceps muscle were incubated with 20 l of CaM-agarose with or without 1 mM CaCl 2 overnight. Pre-IPs, IPs, and post-IPs were then analyzed by immunoblotting with selected antibodies, as previously described (34) .
Statistical analyses. Results are means Ϯ SE. Statistical testing was performed using unpaired t-tests or two-way ANOVA as appropriate. Interactions were evaluated by analyzing each time point separately using Tukey's honest significant difference post hoc test. An underlined symbol denotes bars that meet the criteria represented by that symbol. Statistical evaluation was performed using SPSS 13.0 (SPSS). The significance level was set at ␣ ϭ 0.05.
RESULTS
Hypothesizing that intense electrical stimulation protocols may have concealed or eliminated effects of KN compounds on AMPK signaling in previous studies, we investigated the effect of KN-93 on AMPK signaling and contraction-stimulated glucose uptake during relatively gentle (1 s/15 s) tetanic stimulation ex vivo (Fig. 1) . In both soleus and EDL muscles, preincubation with KN-93 potently reduced AMPK phosphorylation at 2 min while having no significant effects at 10 min. The decrease in AMPK phosphorylation reflected reductions in both ␣ 1 -and ␣ 2 -AMPK activities (Fig. 1, B and C) . AcetylCoA carboxylase (ACC)␤ Ser 221 phosphorylation mirrored these findings (data not shown). The contraction-stimulated increase in glucose uptake in both soleus and EDL muscles was strongly inhibited by KN-93 at both 2 and 10 min (Fig. 1D) . These results show that KN-93 is a potent inhibitor of AMPKdependent signaling and glucose uptake during low-intensity, short-duration (2 min) contraction ex vivo but suggest the KN-93 effect on contraction-stimulated glucose uptake during prolonged (10 min) contraction presumably cannot be explained by AMPK inhibition.
Because KN compounds are Ca 2ϩ /CaM-competitive inhibitors, our KN-93 data suggested that the activation of AMPK at 2 min was Ca 2ϩ /CaM-dependent. Because of their Ca 2ϩ /CaM dependency and confirmed role as AMPKKs, CaMKKs seemed a probable target of KN compounds. Therefore, we attempted to confirm protein expression of CaMKKs in mouse skeletal muscle (Fig. 2) . Using two commercially available antibodies against CaMKK␣ and -␤, both capable of immunoprecipitating Ca 2ϩ /CaM-dependent CaMKI kinases ( Fig. 2A) , we could occasionally, but not consistently, detect CaMKK␣ and -␤ in mouse skeletal muscle by Western blotting (data not shown). Instead, we showed that IP enrichment/post-IP depletion of the immunoprecipitated CaMKI kinases is detected by another pan-CaMKK antibody (Fig. 2B) , showing that the latter antibody recognizes the same antigen as the former. Unlike the isoform-specific antibodies, this pan-CaMKK antibody consistently detects bands around the expected molecular weight in skeletal muscle (compare Fig. 2 , B and C, with Fig   2D) . Also, as previously reported for human skeletal muscle (34), we show in mouse skeletal muscle that CaM affinity precipitation (CaM-AP) enhances the signal detected by the pan-CaMKK antibody in a Ca 2ϩ -dependent manner, showing that it is a Ca 2ϩ /CaM-binding protein (Fig. 2D) . A separate experiment confirmed that recombinant CaMKI alone is unable to autophosphorylate in the presence of Ca 2ϩ /CaM (data not shown).
We tried to evaluate CaMKI signaling in mouse skeletal muscle as a measure of CaMKK activity using a phosphospecific antibody. However, although this antibody clearly detects recombinant CaMKI phoshorylation, neither this antibody nor a total CaMKI antibody detects enrichment of CaMKI in CaM-APs, suggesting very little CaMKI protein in skeletal muscle (Fig. 2D) . This is consistent with our previous work showing CaM-AP enrichment of CaMKI in rat brain, but not human skeletal muscle, using an antibody against total CaMKI (34) .
CaMKII is likely an important CaMK in skeletal muscle, and CaMKII phospho-Thr 287 is clearly increased by contraction in rats ex vivo and in vivo (41, 56, 57) and during human exercise (33, 34) . We confirmed CaMKII expression and CaM-AP enrichment of CaMKII in mouse skeletal muscle (Fig. 2D) . Surprisingly, however, we had difficulties confirming a contraction-induced increase in CaMKII phosphorylation in our incubated mouse muscles. On further investigation, this was likely because 1 h of incubation suspended in our incubation apparatus at resting tension increased basal CaMKII phosphorylation (Fig. 3A) . Interestingly, the increase in CaMKII phosphorylation was not seen when the muscles were allowed to hang slack in the incubation chambers (Fig. 3A) , suggesting that the increase in CaMKII phosphorylation was stretchdependent. Importantly, the increased activation of signaling proteins was not a general phenomenon, since AMPK phosphorylation was not increased during 1 h of incubation (Fig.  3B) . Because of the uncertain nature of the rise in CaMKII phosphorylation, we decided not to evaluate CaMKII phosphorylation during contraction in our model. Meanwhile, the rise in CaMKII phosphorylation in the face of similar or even decreasing 2-DG uptake during the 1st h of incubation (data not shown), if anything, implies that CaMKII activation is not sufficient to increase glucose uptake. However, CaMKII Thr 287 phosphorylation may not be a good measure of in vivo CaMKII activity, as suggested previously by our group (34) .
To further explore whether the KN-93 inhibition of AMPK phosphorylation was CaMKK dependent, the effect of the CaMKK inhibitor STO-609 on AMPK signaling and contraction-stimulated glucose uptake was investigated. This experiment revealed that STO-609 had inhibitory effects on AMPK signaling and contraction-stimulated glucose uptake similar to those seen with KN-93 (Fig. 4) . Hence, in both soleus and EDL muscles, AMPK phosphorylation was potently inhibited at 2 min and less potently at 10 min (Fig. 4A) . As with KN-93, this reflected inhibition of both ␣ 1 -and ␣ 2 -AMPK activity, which were significantly inhibited at 2 and 10 min (Fig. 4, B and C) . Phosphorylation of ACC␤ largely mirrored the AMPK phosphorylation data but only reached significance at 2 min (data not shown). STO-609 significantly inhibited the contraction stimulation of glucose uptake at 2 min in soleus muscle, but not in EDL, while having a partial effect on contraction-stimulated glucose uptake at 10 min in both muscles (Fig. 4D) . Importantly, neither KN-93 nor STO-609 affected basal 2-DG uptake (data not shown).
To confirm that the inhibition of AMPK phosphorylation by KN-93 and STO-609 is not because of inhibition of LKB1, two approaches were taken (Fig. 5) . First, because AICAR-stimulated glucose uptake critically depends on LKB1 (37), we reasoned that AICAR stimulation of glucose uptake should not be inhibited by either inhibitor ex vivo. Indeed, neither KN-93 nor STO-609 significantly inhibited the AICAR stimulation of glucose uptake in either soleus or EDL muscle (Fig. 5A) . Furthermore, we confirmed that neither KN-93 nor STO-609 had discernible effects on AICAR-stimulated AMPK phosphorylation ex vivo (Fig. 5B) . Also, no significant effect of KN-93 or STO-609 on AICAR-stimulated ACC␤ Ser 221 phosphorylation was found (data not shown). Second, we assessed the effect of KN-93 and STO-609 on the activity of recombinant LKB1/MO25/STRAD against LKBtide in vitro (Fig. 5C ). Although neither KN-93 nor STO-609 significantly inhibited LKB1 activity at the 10 and 5 M concentrations used during incubation in this study, STO-609 did significantly inhibit LKB1 activity at 10 M and above. Because the effect of allosteric regulators on LKB1 activity differs markedly de- pending on the substrate chosen (13, 46) , we also confirmed that phosphorylation of recombinant ␣ 1 ␤ 1 ␥ 1 -AMPK by recombinant LKB1 is not affected by 5 M STO-609 or 10 M KN-93 (data not shown).
Finally, to evaluate the possible AMPK dependency of the KN-93 and STO effects on contraction-stimulated glucose uptake, the effect of the inhibitors on glucose uptake was evaluated in mice overexpressing a muscle-specific kinase dead AMPK construct (Fig. 6) . The KD AMPK construct displaces endogenous ␣ 2 -AMPK, thereby greatly reducing total ␣ 2 -AMPK activity in basal (82 and 89% lower vs. wild-type soleus and EDL, respectively) and contracted (70 and 89% lower vs. wild-type soleus and EDL at 10 min, respectively) muscles (Fig. 6A) . This occurs concomitantly with large reductions in ␣ 1 -AMPK activity in basal (68 and 59% lower vs. wild-type soleus and EDL, respectively) and contracted (42 and 65% lower vs. wild-type soleus and EDL at 10 min, respectively) muscle as well (Fig. 6B) . To what extent the remaining ␣ 1 -and ␣ 2 -AMPK activities stem from extramuscular tissues cannot be evaluated using the current technique but has been estimated to be a significant proportion (16) . Compared with the corresponding wild-type glucose uptakes in Fig. 1 , the increase in glucose uptake in muscles expressing KD AMPK was 74% lower in soleus at 2 min and 76 and 29% lower in soleus and EDL, respectively, at 10 min (contraction ϫ genotype interaction; P Ͻ 0.01 in soleus and P Ͻ 0.05 in EDL). Inhibition of glucose uptake was significantly greater in KD AMPK-expressing soleus compared with EDL. Interestingly, neither KN-93 nor STO-609 further reduced glucose uptake in KD AMPK muscles at 2 or 10 min (Fig. 6, C and D) . The lack of inhibition in muscles, which already have greatly reduced AMPK activity, suggests that the inhibitory effects of KN-93 and STO-609 on glucose uptake require inhibition of AMPK, at least in mouse skeletal muscle.
A recent study in a kinase-dead AMPK-overexpressing mouse model similar to KD AMPK mice used in this study, the ␣ 2 i transgenic mice, has suggested than the reduction in glucose uptake seen in these mice may be related to reduced total force production (16) . Using the current protocol, an ϳ15% lower total force development was observed in EDL muscle, but not soleus, from KD AMPK compared with wild-type mice (soleus wild type vs. KD AMPK, DMSO: 43.2 Ϯ 3.8 vs. 
DISCUSSION
This study demonstrated that inhibition of Ca 2ϩ /CaM-dependent signaling in skeletal muscle potently inhibits AMPK phosphorylation and activation at the onset of mild tetanic contraction. Furthermore, our approach combining pharmacological inhibition and AMPK-deficient mice suggests that Ca 2ϩ and AMPK signaling to glucose uptake may be partly serial connected in mice rather than parallel as proposed for rats (56, 57) . This is particularly evident in soleus muscle, suggesting that AMPK is a major mediator of contraction-stimulated glucose uptake in oxidative mouse muscle ex vivo.
Although several studies have shown that Ca 2ϩ signaling to AMPK can occur through the CaMKKs in various cell types (18, 21, 22, 54) , Sakamoto and colleagues (37) showed a striking lack of ␣ 2 -AMPK phosphorylation during intense in situ electrical stimulation in EDL muscles from LKB1-deficient mice, suggesting that LKB1 is the principal donor of AMPKK activity in mouse skeletal muscle during contraction. However, they also recently reported that mice lacking LKB1 expression in heart retain the ability to activate the ␣ 1 -AMPK isoform (38) , leading to the proposal that skeletal muscle ␣ 1 -AMPK may also be regulated by a kinase distinct from LKB1. We concur with this notion, because the skeletal muscle AMPK activity data from LKB1-deficient mice (37) were produced in muscles contracted in situ, where little to no changes occurred in ␣ 1 -AMPK activity, in contrast to the rapid increases in both ␣ 1 -and ␣ 2 -AMPK activity seen with ex vivo contraction (1, 26, 32, 36, 52, 53) . Furthermore, the AMPK activities in mice lacking LKB1 were measured in EDL muscle, where we generally see less potent KN-93/STO-609 inhibition of AMPK phosphorylation and activity compared with soleus muscle. Finally, a recent paper by Koh and colleagues (28) directly demonstrated that muscle-specific LKB1 KO mice retain some ability to phosphorylate and activate ␣ 1 -AMPK in response to contraction and AICAR in skeletal muscle (28) .
Unlike an earlier study (18) , we can detect CaMKK protein in mouse skeletal muscle lysates (34) . CaMKKs fit the criteria of being inhibited by STO-609 and presumably the CaMcompetitive KN-compounds (9, 29, 50) , although a direct effect on CaMKK by the latter remains to be confirmed by in vitro studies. Therefore, we propose the involvement of CaMKK(s) in the regulation of Thr 172 ␣-AMPK phosphorylation in mouse skeletal muscle. A working model in which an intensity-and/or time-dependent switch occurs in the relative importance of AMPKKs during contraction may explain why AMPK phosphorylation during ex vivo contraction is only potently inhibited at 2 min compared with 10 min. Alternatively, signaling through LKB1 could be regulated in an intensity-and/or time-dependent manner. Interestingly, TAK1, also known as MAP3K7, was recently suggested to regulate AMPK activity either directly (30) or indirectly by regulating LKB1 activity (58) . K ϩ depolarization has been shown to increase TAK1 phosphorylation in a KN-93-sensitive manner in HEK293 cells, and dominant-negative CaMKII expression reduces Wnt-5a-stimulated TAK1 phosphorylation (23), suggesting that CaMKII signals upstream of TAK1. Furthermore, a range of AMPK-activating stimuli, including oligomycin, metformin, AICAR, and ischemia, increase TAK1 activity in cardiomyocyte cell culture (58) . Therefore, an alternative model, consistent with available data, is that a CaMKII-TAK1 pathway regulates AMPK phosphorylation directly or through LKB1, with the KN effect observed in the present study being on TAK1 and an unspecific effect of STO-609 on either TAK1 or LKB1. However, small-interfering RNA-mediated reduction in CaMKK protein largely reduces Ca 2ϩ -activated AMPK phosphorylation in LKB1-deficient HeLa cells, suggesting that the Ca 2ϩ -mediated AMPK activation, at least in these cells, requires CaMKK (18, 22, 54) . Therefore, we presently consider CaMKK the more likely non-LKB1 AMPKK candidate in skeletal muscle. Genetically modified models will be needed to clarify the importance of CaMKKs, LKB1, and TAK1 in ␣-AMPK isoform-specific activation during various stimulation regimens in skeletal muscle.
Based on studies using KN compounds, Wright and coworkers (56, 57) have proposed the involvement of CaMKII in contraction-stimulated glucose uptake in rat skeletal muscle. Unlike the present study, they did not find a reduced AMPK phosphorylation by KN compounds following 10 min of intense ex vivo contraction. Meanwhile, this is consistent with our model of an intensity-and/or time-dependent switch in AMPKK. Then again, fiber-type composition of mouse and rat muscles is not directly comparable, for instance rat soleus is of a more oxidative phenotype (ϳ80% type I fibers; see Ref. 44 ) compared with mouse soleus (37% type I fibers; see Ref.
2). Also, a genuine species difference in AICAR-stimulated AMPK signaling to glucose uptake may exist, since AICAR potently stimulates glucose uptake in mouse soleus (26), but not in most studies using rat soleus (12, 15, 27) , despite potent AMPK activation by AICAR in both species. Regardless, the inhibition of AMPK activation by KN-93 reported here suggests that KN-93 may not be a suitable tool when attempting to dissect out the relative importance of CaMKs and AMPK. Previous studies in isolated rat soleus and epitroclearis muscles (7, 56, 57) have shown that increases in sarcoplasmatic reticulum (SR) Ca 2ϩ release by subcontraction caffeine concentrations increases 2-DG uptake without stimulating AMPK phosphorylation, providing a strong argument against Ca 2ϩ -dependent AMPK activation. However, in our hands, AMPK phosphorylation and activity of ␣ 1 -AMPK, but not ␣ 2 -AMPK, consistently increase in isolated rodent soleus muscles after subcontraction caffeine treatment (24), suggesting type 2 errors because of a low number of observations in the previous studies. Interestingly, hypoxia increases intracellular Ca 2ϩ concentrations in rat epitroclearis muscle (47) , and hypoxia-stimulated glucose uptake is inhibited by both KN compounds and the SR-Ca 2ϩ release inhibitor dantrolene in rat soleus and epitroclearis muscles (6, 8) as well as by KD AMPK expression in mouse muscles (31) . Furthermore, H 2 O 2 -treatment of muscle cells increases Ca 2ϩ release from the SR (14, 20) and activates ␣ 1 -AMPK and glucose uptake, independent of ␣ 2 -AMPK, in isolated rat epitroclearis (51) , and N-acetylcysteine, a nonspecific antioxidant, inhibits contraction-stimulated AMPK phosphorylation and activity in mouse EDL (39) . Together, these findings suggest that hypoxia and H 2 O 2 could signal to AMPK through a SR-Ca 2ϩ releasedependent pathway.
Although the effect of STO-609 on AMPK activation generally mirrored the inhibition of glucose uptake, KN-93 still inhibited glucose uptake at the 10-min time point at which KN inhibition of AMPK activation was no longer apparent, suggesting an AMPK-independent inhibition of glucose uptake. This observation is hard to reconcile with the finding that KN-93 and STO-609 do not reduce contraction-stimulated glucose uptake further in KD AMPK-expressing mice. Therefore, an involvement of other Ca 2ϩ /CaM-dependent signaling proteins, including CaMKII, in contraction-stimulated glucose uptake cannot be ruled out at present. It is worth mentioning that the specificity of KN compounds has been questioned, based on their ability to inhibit insulin-stimulated glucose uptake in rat soleus and epitroclearis muscle in some (55), but not all, studies (57) . However, the observation that KN-93 and STO-609 reduce contraction-stimulated glucose uptake in wild-type muscle, while having no effect in the KD AMPK mice or on AICAR-stimulated glucose uptake, suggests that the KN inhibition seen is not a direct effect on the glucose uptake machinery.
Previous ex vivo studies have generally used very intense protocols designed to elicit a maximal response in glucose uptake (16, 37, 56) . As shown here, this may conceal physiologically important signaling mechanisms because of redundant signaling and/or time effects, in particular during the intricate multipathway contraction-signaling process. In addition, it is not known how well the reductionistic ex vivo contraction approach extrapolates to in vivo exercise in mice and ultimately in humans. Much to our surprise, we have recently observed no difference in exercise-stimulated 2-DG uptake in various muscles from catherized running KD AMPK mice compared with wild-type mice (S. B. Jørgensen, J. T. Treebak, T. E. Jensen, E. A. Richter, and J. P. F. Wojtaszewski, unpublished observation), even in soleus muscle, suggesting that glucose uptake regulation may differ markedly between the ex vivo and in vivo setting. Therefore, although the ex vivo contraction model remains a valuable tool in the attempt to dissect out the crucial components of contraction signaling, it remains imperative that the ex vivo findings are followed up with studies in more physiological in vivo systems as well.
In conclusion, the current study proposes as a working model that one or more CaMKKs act as AMPKKs at the onset of mild tetanic contraction and play a role in the regulation of AMPK-dependent contraction-stimulated glucose uptake in mouse skeletal muscle ex vivo.
